Frank Gaffney, MD
Cardiovascular Disease · Tulsa, OKNPI 1609846112
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $194,376 of the $210,943 with a category attached, or 92.1%. 24 manufacturers reported payments, led by Boehringer Ingelheim at 42.6% of the total. Reporting peaked in 2019 at $69,178 and has fallen 60.3% since, to $27,437 in 2025. Among cardiovascular disease clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 317 payments — averaging $665.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$90K
- Johnson & Johnson$58K
- Lilly USA, LLC$33K
- Bayer$16K
- Pfizer$7K
- AstraZeneca$6K
- plus $2K from 18 others
Across 25 payments — averaging $1274.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$32K
What the payments were for
- Consulting fees$4,0002%
- Speaking & faculty fees$194,37692%
- Travel & lodging$5,8923%
- Food & beverage$6,6413%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 100 | $89,900 |
| Johnson & Johnson | 50 | $57,781 |
| Lilly USA, LLC | 37 | $32,514 |
| Bayer | 19 | $15,773 |
| Pfizer | 11 | $6,957 |
| AstraZeneca | 8 | $5,963 |
| E.r. Squibb & Sons, L.L.C. | 9 | $352 |
| Novartis | 37 | $323 |
| Novo Nordisk | 6 | $314 |
| Abbott | 7 | $217 |
| Merck | 3 | $155 |
| Amgen | 6 | $122 |
| Heartflow, Inc. | 1 | $121 |
| Boston Scientific | 4 | $109 |
| Scpharmaceuticals Inc. | 4 | $65 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $64 |
| Lexicon Pharmaceuticals, Inc. | 2 | $51 |
| Medtronic(2 entities) | 2 | $40 |
| Amarin Pharma, Inc. | 2 | $36 |
| Lantheus Medical Imaging, Inc. | 1 | $24 |
| Kls-martin L.p. | 1 | $20 |
| Edwards Lifesciences | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Inari Medical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$210,943 in reported general payments places this provider in the 95th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 325 | $300,466 |
| XareltoRivaroxaban | 108 | $139,738 |
| EntrestoSacubitril/Valsartan | 119 | $106,997 |
| JardianceEmpagliflozin | 82 | $69,937 |
| Repatha SureclickEvolocumab | 25 | $18,976 |
| WegovySemaglutide | 11 | $14,688 |
| BrilintaTicagrelor | 18 | $13,474 |
| Praluent PenAlirocumab | 20 | $11,894 |
| Ezetimibe | 119 | $3,888 |
| Atorvastatin Calcium | 296 | $3,704 |
| Metoprolol Succinate | 242 | $2,962 |
| Nebivolol Hcl | 62 | $2,757 |
| Rosuvastatin Calcium | 142 | $2,382 |
| Carvedilol | 201 | $1,904 |
| ClopidogrelClopidogrel Bisulfate | 126 | $1,816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $6,957 | $300,466325 claims |
| Johnson & JohnsonXarelto | $57,781 | $139,738108 claims |
| NovartisEntresto | $323 | $106,997119 claims |
| Boehringer IngelheimJardiance | $89,900 | $69,93782 claims |
| Novo NordiskWegovy | $314 | $14,68811 claims |
| AstraZenecaBrilinta | $5,963 | $13,47418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Tulsa
- Mohamad KhattabTulsa$47K
- Steve KimTulsa$38K
- Eric AuerbachTulsa$35K
- David WilkettTulsa$25K
- Daniel WildesTulsa$24K
- Thomas KalapuraTulsa$17K
- Heather ChaTulsa$16K
- Christopher HigginsTulsa$13K
- Alan KaneshigeTulsa$11K
- Neil AgrawalTulsa$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.